GeneBioTech Co. Ltd Total Assets
GeneBioTech Co. Ltd total assets. Based on the latest financial reports, GeneBioTech Co. Ltd (086060) holds total assets worth ₩80.28 Billion KRW (≈ $54.40 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GeneBioTech Co. Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of GeneBioTech Co. Ltd (2009–2025)
Total assets of GeneBioTech Co. Ltd from 2009 to 2025. This chart illustrates how GeneBioTech Co. Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of GeneBioTech Co. Ltd for real-time trading data and today's change.
GeneBioTech Co. Ltd - Asset Composition Analysis
GeneBioTech Co. Ltd Total Assets Breakdown (December 2025)
GeneBioTech Co. Ltd total assets breakdown as of December 2025. GeneBioTech Co. Ltd's total assets of ₩80.28 Billion consist of 72.3% current assets and 27.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 12.7% |
| Accounts Receivable | ₩12.39 Billion | 16.4% |
| Inventory | ₩14.07 Billion | 18.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩582.66 Million | 0.8% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how GeneBioTech Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of GeneBioTech Co. Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GeneBioTech Co. Ltd's current assets represent 72.3% of total assets in 2025, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 12.7% of total assets in 2025, up from 5.9% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 18.6% of total assets.
GeneBioTech Co. Ltd Competitors by Total Assets
Key competitors of GeneBioTech Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩575.39 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩267.18 Billion |
|
Komipharm International Co. Ltd
KQ:041960
|
Korea | ₩133.92 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩125.25 Billion |
|
Aprogen Healthcare & Games Inc
KQ:109960
|
Korea | ₩324.89 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
GeneBioTech Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.13 | 3.55 | 3.54 |
| Quick Ratio | 2.33 | 2.39 | 2.54 |
| Cash Ratio | 0.00 | 0.00 | 0.67 |
| Working Capital | ₩41.86 Billion | ₩38.44 Billion | ₩27.76 Billion |
GeneBioTech Co. Ltd - Advanced Valuation Insights
This section examines the relationship between GeneBioTech Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.73 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.1% |
| Total Assets | ₩75.63 Billion |
| Market Capitalization | $28.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values GeneBioTech Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: GeneBioTech Co. Ltd's assets grew by 5.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for GeneBioTech Co. Ltd (2009–2025)
The table below shows the annual total assets of GeneBioTech Co. Ltd from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩75.63 Billion ≈ $51.26 Million |
+5.06% |
| 2024-12-31 | ₩71.99 Billion ≈ $48.79 Million |
+9.05% |
| 2023-12-31 | ₩66.02 Billion ≈ $44.74 Million |
+3.09% |
| 2022-12-31 | ₩64.04 Billion ≈ $43.40 Million |
+6.08% |
| 2021-12-31 | ₩60.37 Billion ≈ $40.91 Million |
-2.77% |
| 2020-12-31 | ₩62.09 Billion ≈ $42.07 Million |
-8.61% |
| 2019-12-31 | ₩67.93 Billion ≈ $46.04 Million |
-6.46% |
| 2018-12-31 | ₩72.63 Billion ≈ $49.22 Million |
+21.97% |
| 2017-12-31 | ₩59.54 Billion ≈ $40.35 Million |
+0.65% |
| 2016-12-31 | ₩59.16 Billion ≈ $40.09 Million |
+20.21% |
| 2015-12-31 | ₩49.21 Billion ≈ $33.35 Million |
+3.94% |
| 2014-12-31 | ₩47.34 Billion ≈ $32.08 Million |
-2.08% |
| 2013-12-31 | ₩48.35 Billion ≈ $32.77 Million |
+5.63% |
| 2012-12-31 | ₩45.78 Billion ≈ $31.02 Million |
-1.07% |
| 2011-12-31 | ₩46.27 Billion ≈ $31.36 Million |
+56.51% |
| 2010-12-31 | ₩29.56 Billion ≈ $20.03 Million |
+0.69% |
| 2009-12-31 | ₩29.36 Billion ≈ $19.90 Million |
-- |
About GeneBioTech Co. Ltd
Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. It offers functional feed ingredients and additives, as well as veterinary medicines. The company was founded in 1984 and is headquartered in Gongju, South Korea.